News about "GSK"

Samsung Biologics Expands US Manufacturing with HGS Acquisition from GSK

Samsung Biologics has acquired Human Genome Sciences (HGS) from GSK, securing its first US-based manufacturing site and strengthening its global supply network. The company plans further investments to expand capacity and capabilities at the facility, reinforcing its long-term commitment to the US biopharmaceutical manufacturing ecosystem.

GSK | 22/12/2025 | By News Bureau

GSK, Fleming Initiative Launch AI-Driven Grand Challenges to Target AMR

These initiatives bring together leading scientific expertise and advanced technologies—including AI—to tackle urgent gaps in antibiotic discovery, fungal infection treatment, immune response understanding, disease prediction, clinical prescribing, and global policy engagement.

GSK | 19/11/2025 | By Darshana |  126

GSK and Empirico Sign Licensing Deal for Respiratory Oligonucleotide

Oligonucleotide therapies, including siRNA, offer the potential to modulate gene expression and target diseases beyond the reach of traditional drugs. EMP-012 adds to GSK’s growing oligonucleotide pipeline across respiratory, immunology and inflammation, and infectious disease portfolios.

GSK | 29/10/2025 | By Dineshwori |  125

GSK Gains Exclusive Rights to Syndivia's Prostate Cancer ADC

GSK has obtained exclusive rights from Syndivia for a preclinical Antibody-Drug Conjugate (ADC) targeting metastatic Castration-Resistant Prostate Cancer (mCRPC), addressing an urgent need for novel therapies. The agreement expands GSK’s oncology pipeline with a potential best-in-class ADC designed to deliver enhanced anti-tumour activity.

GSK | 27/10/2025 | By Dineshwori |  201

China Approves GSK's Shingrix for Shingles Prevention

The China National Medical Products Administration (NMPA) has approved GSK’s Shingrix (Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster) in adults aged 18 years and over who are at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy.

GSK | 15/10/2025 | By Dineshwori |  326

South Korea's GC Biopharma Secures CMO Rights for Curevo's Shingles Vaccine

South Korean biopharmaceutical company GC Biopharma has signed a contract manufacturing agreement with Curevo Vaccine to produce amezosvatein (development name: CRV-101), a recombinant shingles vaccine currently under clinical development.

GSK | 13/10/2025 | By Dineshwori |  220

GSK to submit label update for Wellcovorin at US FDA's request

GSK will file an sNDA with the US FDA to update Wellcovorin’s label to include Cerebral Folate Deficiency, following the agency’s request under its initiative to repurpose older drugs for chronic conditions.

GSK | 24/09/2025 | By Dineshwori |  129

GSK to Invest USD 30 Billion in US R&D and Supply Chain Over Next 5 Years

GSK has announced plans to invest USD 30 billion across the United States over the next five years to strengthen its R&D, drug discovery, development, and clinical trial activity.

GSK | 17/09/2025 | By Dineshwori |  177

Hengrui Pharma and GSK Partner to Develop 12 Innovative Drugs Across Respiratory, Immunology and Oncology

Hengrui Pharma has signed agreements with GSK to develop up to 12 innovative medicines across respiratory, immunology and inflammation, and oncology. It includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD and additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK.

GSK | 28/07/2025 | By Mrinmoy Dey |  171

Pharma Leaders Back UK Life Sciences Strategy, But ABPI Warns of Medicines Investment Gap

Pharmaceutical and medical technology leaders, including GSK, Sandoz, Accord Healthcare, Becton Dickinson, and Celltrion have welcomed the UK government’s new Life Sciences Sector Plan, recently unveiled as part of its flagship Industrial Strategy.

GSK | 19/07/2025 | By Dineshwori |  158